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Abstract
Background—Good decision making about prostate-specific antigen (PSA) screening involves
men considering how they value the different potential outcomes. The effects of different methods
of helping men consider such values, however, is not clear.
Methods—We conducted a randomized trial to compare three methods of values clarification for
decision making about PSA screening in average-risk men ages 50-70 from the US and Australia.
Participants were drawn from online panels from a survey research firm in each country and were
randomized by the survey firm to one of three values clarification methods (VCM): 1) a balance
sheet, 2) rating and ranking task, and 3) a discrete choice experiment (DCE). The main outcome
was the difference among groups in most important attribute, based on a single question post-
VCM. Secondary outcomes include differences in unlabelled test choice and intent to screen.
Results—We enrolled 911 participants. Mean age was 59.8 years; most were Caucasian and over
one-third graduated from college. Over 40% reported a PSA test within 12 months. Those who
received the rating and ranking task (n= 307) were more likely to report reducing the chance of
death from prostate cancer as being most important (54.4%), compared with either the balance
sheet (n= 302, 35.1%) or DCE (n= 302, 32.4%) groups. (p< 0.0001) Those receiving the balance
sheet were more likely (43.7%) to prefer the unlabelled PSA-like option (as opposed to the “no
screening”-like option) compared with those who received rating and ranking (34.2%) or the DCE
(20.2%). However, the proportion who intended to have PSA testing was high and did not differ
between groups (balance sheet 77.1%; rating and ranking 76.8%; DCE 73.5%, p = 0.731).
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Conclusions—Different values clarification methods produce different patterns of attribute
importance and different preferences for screening when presented with an unlabelled choice.
Background
Whether to undergo prostate-specific antigen (PSA) screening is a difficult decision for
middle-aged men. Prostate cancer is common, and causes over 28,000 deaths per year in the
United States.1 However, PSA screening at best seems to produce only a small reduction in
prostate cancer mortality and has considerable downsides.2 These downsides include
increases in the number of prostate biopsies (which can be painful and have a risk of causing
infection); over-diagnosis, (i.e., the detection of cancers that would never become clinically
apparent or problematic); and increased treatment and treatment-related adverse effects
(impotence and incontinence).3
High-quality decision processes, including whether or not to be screened for prostate cancer,
should inform patients and incorporate patient values.4,5 Decision aids are tools that have
been developed to help inform patients of their options related to preference-sensitive
decisions, promote understanding of the benefits and downsides of these options, prompt
consideration of one’s personal values, and encourage shared decision making.5 Decision
aids have been shown to improve patient knowledge, reduce uncertainty and decisional
conflict, and promote a shared decision making process for a range of conditions, including
PSA screening.6,7
Consensus recommendations for high-quality decision aid design include incorporating
some method for eliciting and clarifying patient values and preferences.5 However, the best
method for eliciting and incorporating patient values and preferences is not clear.8, 9
Potential options for values elicitation include implicit techniques, in which patients receive
information about different domains and are able to consider their potential value on their
own (or with a prompt to “consider which factors are most important to you”), and several
explicit techniques (e.g. rating, ranking, discrete choice methods) in which patients are
asked specifically to compare the relative importance of several potentially relevant
characteristics of a decision. Among decision psychologists, there remains considerable
theoretical debate about the potential benefits and downsides of explicit techniques.10
Few previous studies have examined the effect of a decision aid with explicit values
clarification compared with the same decision aid without explicit values clarification, or
compared different values clarification techniques against one another. A recent review11
identified 13 comparative trials, and could not reach a conclusion about the effects of values
clarification, as outcome measurement was inconsistent and results mixed. One of these
studies12 examined PSA screening, and found no effect of adding a time trade-off task on
knowledge, decisional conflict, or testing preference. In a small, single-site trial, we recently
compared two different explicit techniques (discrete choice experiment vs. rating and
ranking) for decision making about colorectal cancer screening and found some differences
in reported most important attribute, but few other effects.13
To help better understand the effect of different values clarification methods, we conducted
a randomized trial comparing an implicit method (provision of a balance sheet) and two
explicit methods (a rating and ranking task and a discrete choice experiment) to determine
whether they produce different effects on decision making about PSA screening.
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We performed a randomized trial among male members of an online survey panel in the US
and Australia who had indicated a willingness to complete surveys. Participants were asked
to complete a baseline questionnaire, review basic information about the PSA decision,
work through their assigned values clarification task, and then complete a post-task
questionnaire.
Selection of attributes and levels
We described PSA screening decision options in terms of 4 key attributes: effect on prostate
cancer mortality risk of biopsy, risk of being diagnosed with prostate cancer, and risk of
becoming impotent or incontinent as a result of treatment. The attributes and the range of
levels of the attributes included were based upon the existing literature, including recently
reported randomized trials, and our own previous work. 14-16 See Table 1.
Balance Sheet Task
The balance sheet was based on modelling studies of PSA-related outcomes14, and was
informed by randomized trials and observational evidence, as well as by our previous
research in this area.16 (See Figure 1)
Rating and Ranking Task
The rating and ranking task asked participants to rate (on a scale of 0= not important at all to
5 = very important) and then rank the three most important screening test attributes from sets
of the key attributes. (See Figure 2)
Discrete choice experiment task
In discrete choice experiments (also known as choice-based conjoint analysis), respondents
are asked to choose between hypothetical alternatives defined by a set of attributes.17-20 The
method is based on the idea that goods and services, including health care services, can be
described in terms of a number of separate attributes or factors. The levels of attributes are
varied systematically in a series of questions. Respondents choose the option that they prefer
for each question. People are assumed to choose the option that is most preferred, or has the
highest “value” or “utility.” From these choices, a mathematical function is estimated which
describes numerically the value that respondents attach to different choice options. Our
study followed the ISPOR Guidelines for Good Research Practices for conjoint analysis in
health.20
For the DCE, we used NGENE (www.choice-metrics.com) to generate a statistically
efficient choice design that minimized sample size.21, 22 Our design required all participants
in the DCE group to evaluate a set of 16 choice scenarios. An example choice task is shown
in Figure 3. Each task included an active screening option and a fixed “no screening” option.
Pretesting
We used online panels maintained by an international research firm, Survey Sampling
International (SSI) to recruit 60 men (30 US, 30 Australia) to pre-test the surveys. Pilot data
indicated that respondents were able to complete the values clarification tasks without
difficulty. Based on information garnered from the pre-test, we modified the survey
language slightly and removed the “I prefer neither option” response. Parameter estimates
from analysis of the discrete choice pilot data were used to inform the final efficient design
of the discrete choice task for the main study.
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Participant eligibility and recruitment
We used the SSI online panels to recruit a target of 900 men (450 US, 450 Australia).
Participants were average risk (no personal or family history of prostate cancer) and were
originally targeted to be between the ages of 50 and 75; however, because SSI has few
potential participants over age 70, the sample was instead drawn from men 50-70. Prior
testing history was assessed but not used to determine eligibility. Those with visual
limitations or inability to understand English were excluded.
Study flow
The entire study was performed online. After eligibility was determined and consent
obtained, participants received basic information about prostate cancer and PSA screening
(See eFigure 1), completed basic demographic questions, and were then randomized by SSI
on a 1:1:1 basis, stratified by country, to: 1) an implicit values clarification method (a
balance sheet of key test attributes); 2) a rating and ranking task; or 3) a discrete choice
experiment (DCE). Upon task completion, participants then completed the post-task
questionnaire.
Study Outcomes
Our main outcome of interest was the participant reported most important attribute (“Which
ONE feature of prostate cancer screening is most important to you?” with responses chosen
from: the chance of being diagnosed, the chance of dying over 10 years, the chance of
requiring a biopsy from screening, the chance of becoming impotent or incontinent from
treatment). We chose this outcome to determine if the values clarification method itself
influenced how participants valued key features of the decision. Key secondary outcomes
included testing preference, based on a question that included two unlabelled options
described in terms of the key decision attributes and designed to mimic screening or no
screening options (Figure 4) - we call this “unlabelled test preference”; the values clarity
sub-scale of the Decisional Conflict Scale (DCS), which ranges from 0 to 100 with lower
scores suggesting better clarity; and a single question about intent to be screened with PSA,
based on a Likert scale (from strongly disagree to strongly agree, with agree and strongly
agree considered as positive intent to be screened and as their labelled preference). In
addition, we also report certain VCM task-specific outcomes.
Statistical Analysis
We performed initial descriptive analyses with means and proportions. We used chi square
and ANOVA for bivariate analyses across the three groups. Because of baseline
demographic differences among groups, we then performed multivariate analyses using
logistic regression, and adjusting for potential confounders, including age, race, education,
income, and prior PSA testing. We also examined whether there was effect modification
based on prior PSA screening or country. Because we identified no important effect
modification, we present non-stratified results here. A separate paper will examine
differences in study outcomes for US vs. Australian participants. We used a mixed
multinomial logit (MMNL) (also known as a random parameters logit) model with a panel
specification23, 24 to assess differences in preference structure between respondents from the
US and Australia within the DCE arm (see eAppendix for details).
Ethical considerations
This study was approved by the University of North Carolina- Chapel Hill Institutional
Review Board on April 28, 2011 (Study number 11-0861) and is registered through
ClinicalTrials.gov site (NCT01558583).
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We screened 2,336 individuals from October, 12 – 27, 2011. Of these, 1300 were ineligible
or declined participation and 1,036 were randomized. Of these 1,036, 911 (87.9%)
completed the full survey (Figure 5). Mean time to complete the survey was 8 minutes, 46
seconds (range 1:16 – 39:32), and differed between groups (balance sheet 6:58, rating/
ranking 7:57, DCE 11:24, p < 0.0001). Participant characteristics are shown in Table 2. We
noted potentially important differences across randomization groups in the proportion of
White participants and the proportion reporting PSA testing within the past 12 months.
Main outcomes
The three different values clarification methods produced differences in the participant
reported most important attribute from the single post-task questionnaire: those who
received the rating and ranking task were more likely (54.4%) to report reducing the chance
of death from prostate cancer as being most important, compared with either the balance
sheet (35.1%) or DCE groups (32.5%). See Table 3. Adjustment for potential confounders,
including age, race, education, income, and prior PSA testing, did not affect the findings.
In terms of unlabelled test preference, those receiving the balance sheet (43.7%) were more
likely to prefer the PSA-like option (as opposed to the no screening option), compared with
those who received rating and ranking (34.2%) or the DCE (20.2%), p < 0.0001. Again,
findings were similar after adjustment for potential confounders. Those choosing the
screening option were somewhat more likely to select mortality reduction as most important
(47%) than those choosing the “no screening” option (37%); conversely, those choosing no
screening were more likely to select the chance of developing impotence or incontinence as
most important (22%) compared with those choosing screening (10%).
However, the proportion of participants who agreed or strongly agreed that they intended to
have PSA testing when labelled as such was high and did not differ between groups (balance
sheet 77.1%; rating and ranking 76.8%; DCE 73.5%, p = 0.731) Mean values clarity score
was low (suggesting a high degree of clarity) and did not differ importantly between groups,
despite the difference being statistically significant. (balance sheet 22.5; rating and ranking
19.0; and DCE 20.3, p=0.0276)
Method-specific outcomes
Among the 302 participants randomized to the balance sheet, 65.6% of participants chose
the labelled PSA testing option. Agreement between test preference from the balance sheet
and the unlabelled test preference question was low. (eTable 1.)
For the rating and ranking group (n=307), chance of being diagnosed with prostate cancer
and chance of dying from prostate cancer were each rated slightly higher in importance (3.8
for each) compared with chance of needing a biopsy (3.5) or chance of developing
impotence of incontinence from screening (3.6). A majority (52.8%) of the 302 participants
in this group ranked the chance of dying from prostate cancer as most important. Agreement
between the ranking task and the single question about most important attribute from the
post-task questionnaire was modest: 71 of 307 participants (23%) chose different attributes
as most important on the single question compared with their ranking. (eTable 2).
For the 302 participants randomized to the DCE, the mean part-worth utilities are shown in
eTable 3. All attributes performed in the direction expected: more value was attached to
lower chance of dying from prostate cancer, lower risk of being diagnosed, and lower
chance of impotence or incontinence compared with higher levels. There were no significant
differences in utility based on chance of needing a biopsy. The attribute most likely to be
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chosen as the most important one, based on DCE-derived importance scores, was the chance
of dying from prostate cancer (chosen by 53.5% of participants).
Comment
Different methods of values clarification produced different patterns of attribute importance
and different preferences for PSA testing when presented with unlabelled testing options
designed to correspond to the PSA test and the option of not being screened. Those
receiving the rating and ranking task were more likely to select reduction in prostate cancer
mortality as most important compared with those assigned to the balance sheet or DCE;
those receiving the balance sheet were more likely to select the unlabelled option that
corresponded with the PSA test than those assigned to rating and ranking or the DCE. Those
assigned to the DCE were somewhat less likely to select reduction of mortality as most
important, and were least likely to select the PSA-like option on the unlabelled preference
question. These findings are consistent with the theory that DCE encourages people to more
fully consider all attributes and not rely on simple heuristics.25
However, there was high intent to be screened and no difference between groups when
asked directly with a labelled question. Among those in the balance sheet group, there were
moderately large differences in the proportion selecting PSA screening when it was
presented as a labelled vs. an unlabelled choice. Mean values clarity sub-scale was low
across all three groups, suggesting that most users were clear about their values after
completing their task.
These findings have several implications. First, they suggest that the method of values
clarification chosen affects how participants report their values (in terms of most important
attribute) in this sample of online panel members making hypothetical choices. The DCE
may have led to more deliberation and hence less monolithic results for attribute importance;
conversely, the rating and ranking may have focused respondents more on the most
“accessible” attribute: mortality reduction. Our current study cannot determine which
technique is “better” or a more accurate reflection of each man’s true values; additional,
larger studies should be performed that examine men making actual screening decisions,
account for other factors affecting decisions, and include longitudinal follow-up to allow
measurement of more distal outcomes such as appropriate test use (test received by those
who prefer it and not received by those who choose against it), decision satisfaction, and
decisional regret.
Second, this study shows the potentially large effect of labelling on decision making. The
proportion of men in the balance sheet arm who chose labelled PSA testing on the balance
sheet (65.6%) was higher than the proportion choosing the unlabelled but otherwise identical
PSA-like option immediately afterwards (43.7%). Labelling may affect preferences by
different mechanisms: it can allow decision makers to “value” important aspects of the
decision that are not reflected in the attributes we used to describe the tests – this could be a
desirable effect. However, labelling may also allow decision makers to simply choose the
familiar option, which can help resolve cognitive dissonance but may not reflect one’s
underlying values.26 More studies, including qualitative work, are needed to “unpack” the
causes of this labelling effect.
Our study adds to the limited body of research examining the effects of explicit values
clarification methods, versus no values clarification, implicit methods, or other explicit
methods.11 Other studies have found inconsistent effects of values clarification, including
one study in PSA screening.12
Pignone et al. Page 6













The USPSTF recently revised its PSA screening recommendation for middle-aged men,
changing to a “D” recommendation (against routine screening).27 Although it is clear that
PSA screening has important downsides, the possibility of a rare benefit in terms of prostate
cancer mortality reduction and the preference patterns noted in our survey may warrant a
shared decision making process.
More studies, conducted in a range of different conditions, using a range of different
methods, are required to better determine the best approach (if any) to values clarification.
Decision aids with explicit clarification techniques should be compared against decision aids
with no or only implicit values clarification to best understand their effects on decision
making processes and actual decisions. Because decision aids can be difficult to implement,
especially for common decisions like PSA screening, decision aid developers should only
include values clarification methods if they improve the decision making process in some
meaningful way.
Our study, while helpful in building the evidence base in this area, has a few key limitations
that must be considered. First, we used a hypothetical scenario; whether the effects we
observed would differ in men actually making the screening decision is unknown. To
mitigate this concern, we enrolled only men of screening age and asked them to answer as if
they were actually deciding. Secondly, we cannot directly determine, on an individual level,
whether a good decision making process was followed or whether a good decision was
made; larger studies, with more distal outcomes, are required. Third, we did not conduct our
trial within a full PSA screening decision aid; however, the information that we provided to
participants contained the key elements for a decision aid (definition of the decision, pros
and cons of the options; encouragement to consider one’s values).5 Future studies should
compare different values clarification techniques embedded within a full decision aid.
Fourth, participants in this study were drawn from an online panel and may not be
completely representative of the population of US and Australian middle men in this age
group. Fifth, randomization produced some differences in baseline characteristics between
VCM groups. We adjusted for these differences and did not see effects on our results.
Finally, we did not measure whether our participants were informed and engaged when they
provided their answers.
In conclusion, different values clarification techniques affected how men valued different
aspects of the decision to undergo PSA screening and also influenced unlabelled test choice.
Intent to be screened with PSA was higher than the preference for PSA when assessed via
unlabelled question, suggesting a strong effect of the label itself. Further studies with more
distal outcome measures are needed to determine the best method of values clarification, if
any, for decisions like whether to screen with PSA.
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Rating and ranking task
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Example discrete choice question
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Unlabeled Test Preference Question
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Table 1
Attributes and levels for prostate cancer screening
Attribute Screening Levels No Screening Level
Chance of being diagnosed with prostate cancer over 10 years • 40 in 1000
• 60 in 1000
• 80 in 1000
• 40 in 1000
Chance of dying from prostate cancer over 10 years • 2 in 1000
• 3 in 1000
• 4 in 1000
• 4 in 1000
Chance of having a prostate biopsy as a result of screening over 10 years • 0 in 1000
• 240 in 1000
• 330 in 1000
• 0 in 1000
Chance of becoming impotent or incontinent as a result of screening over 10 years • 0 in 1000
• 10 in 1000
• 20 in 1000
• 0 in 1000
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Table 3
proportion of respondents designating specific attributes as most important (single question) by values
clarification task
Attribute Balance sheet (n=302) Rating and Ranking
(n=307)
DCE (n=302)
Chance of being diagnosed with prostate cancer 35.8% 22.5% 31.3%
Chance of dying from prostate cancer 35.1% 54.4% 32.5%
Chance of requiring a biopsy as a result of screening 10.9% 8.8% 13.9%
Chance of developing impotence or incontinence as a result of screening 18.2% 14.3% 22.5%
Pearson chi2 (6) = 39.9882 p < 0.0001
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